Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
News|Articles|October 9, 2025
Report - Digital Transformation in Biopharma: The Gap Between Hype and Implementation
Author(s)Christopher Cole
Comparing our survey results with recent headlines uncovered biopharma’s digital transformation paradox: high potential vs. low adoption.
Advertisement
Advertisement
As new bio/pharmaceutical manufacturing and development approaches move toward commercialization, traditional industry modalities are under intense pressure (1-7). At the same time, automation, advanced analytics, digital twins, artificial intelligence, and other technologies are evolving quickly and promising to transform how medicines are developed, produced, and delivered.
Related to this article
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
New clinical data highlight improved disease control, reduced eye bulging, and weight-loss benefits, potentially broadening options for patients with unmet needs.
Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Teprotumumab N01 (Sycume) reduced eye bulging in 60.4% of patients with chronic, inactive thyroid eye disease in a phase 3 trial.
New clinical milestones, manufacturing investments, and regulatory incentives could help developers overcome barriers to delivering treatments for patients with rare diseases.
New regulatory decisions, manufacturing partnerships, and financing pressures are reshaping access, supply, and development pathways for emerging advanced therapies.
Caribou is halting vispa-cel and CB-011, allogeneic CAR-T therapies that showed up to 92% response rates, citing a difficult financing environment.
Advertisement
Advertisement